Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
Фаза 4
Завершено
NCT04655170
| Заболевание | COPD Exacerbation |
|---|
| Фаза | Фаза 4 |
|---|
| Спонсор | University of Tennessee Graduate School of Medicine |
|---|
| Статус | Завершено |
|---|
| Участники | 60 участн. |
|---|
| Вмешательство | Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) |
|---|
| Дата начала | 9.12.2020 |
|---|
| Дата завершения | 19.01.2023 |
|---|
| Публикация результатов | 3.08.2026 |
|---|
Кратко
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
Difference in Modified Borg Dyspnea Scale Scores Between Groups
From enrollment to the end of treatment at Day 7 · scores on a scale
| Experimental: Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist) | 1.89 scores on a scale |
|---|
| Active Comparator: Group 2: Ipratropium Bromide (Atrovent) & Albuterol(Ventolin) as Standard of Care | 1.92 scores on a scale |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.